TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Study results from National Institutes of Health broaden understanding of tuberculosis
January 6th, 2009
"Bicyclic nitroimidazoles, including PA- 824, are exciting candidates for the treatment of tuberculosis. These prodrugs require intracellular activation for their biological function," investigators in the United States report. "We found that Rv3547 is a deazaflavin- dependent nitroreductase ( Ddn) that converts PA- 824 into three primary metabolites; the major one is the corresponding des- nitroimidazole ( des- nitro). When derivatives of PA- 824 were used, the amount of des- nitro metabolite formed was highly correlated with anaerobic killing of Mycobacterium tuberculosis ( Mtb). Des- nitro metabolite formation generated reactive nitrogen species, including nitric...
Source: TB & Outbreaks Week (2009-01-06)
|
